# ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer

> **NCT00555919** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 68 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Lonaprisan (ZK 230211, BAY86-5044)
- **DRUG:** Lonaprisan (ZK 230211, BAY86-5044)

## Key facts

- **NCT ID:** NCT00555919
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2010-04
- **Final completion:** 2011-03
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2014-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00555919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00555919, "ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT00555919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*